Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a ...

Current guidelines lack consensus and rely on lower-quality evidence, according to the author of new research.

During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...

A new review article published in Genes & Diseases explores the intricate relationship between non-coding RNAs and oxidative stress in cancer progression shedding new light on the mechanisms that ...

Non-coding RNAs and oxidative stress work together in various stages of cancer progression, including cancer cell growth and reproduction, cancer ...

Learn how new research and clinical trials at Memorial Sloan Kettering Cancer Center (MSK) have helped 32-year-old Giancarlo ...

has been cleared for patients with ROS1-positive non-small-cell lung cancer (NSCLC) on the back of overall response rate (ORR) data from the phase 1/2 TRIDENT-1 study after a priority review by ...

“ROS1-positive NSCLC is a rare form of lung cancer with a unique patient journey to navigate,” said Janet Freeman-Daily, Co-Founder and President of The ROS1ders. “At The ROS1ders, we are ...